We are developing next generation products based on the transformative potential of gene therapy to treat patients with severe genetic and orphan diseases. We have two clinical stage products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease, a preclinical oncology program in partnership with Celgene, a world-class team and a broadly applicable gene therapy platform. READ MORE >>
We are growing and need great talent. With the news of our Celgene partnership, we currently have lots of exciting opportunities in Research, Development, Clinical Operations, Regulatory Affairs, Quality, Process Development and more, including the following positions:
bluebird bio Appoints Two New Members to its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.
bluebird bio Announces Global Strategic Collaboration with Celgene to Advance Gene Therapy in Oncology
bluebird bio to Present at the 31st Annual J.P. Morgan Healthcare Conference